FDA Hatch/Waxman “Moot Court” To Examine Brand/Generic Legal Positions
This article was originally published in The Tan Sheet
Executive Summary
FDA's chief counsel will host a "moot court" briefing on the brand and generic industry's arguments about the agency's interpretation of the Hatch/Waxman Act
You may also be interested in...
Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch
Congress should wait for an upcoming Supreme Court ruling on the Doctrine of Equivalents before beginning serious work on re-drafting the Hatch/Waxman Act, Sen. Orrin Hatch (R-Utah) said
Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch
Congress should wait for an upcoming Supreme Court ruling on the Doctrine of Equivalents before beginning serious work on re-drafting the Hatch/Waxman Act, Sen. Orrin Hatch (R-Utah) said
Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch
Congress should wait for an upcoming Supreme Court ruling on the Doctrine of Equivalents before beginning serious work on re-drafting the Hatch/Waxman Act, Sen. Orrin Hatch (R-Utah) said